Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. NVDA
3. TSLA
4. WBD
5. AMD
6. USO
7. META
8. AMC
9. MSFT
10. ACN

Go back to Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA
LIGAND PHARMA (NASDAQ: LGND) Delayed: 287.07 +3.58 (1.26%)
Previous Close $283.49    52 Week High $139.79 
Open $283.67    52 Week Low $82.07 
Day High $289.47    P/E 667.60 
Day Low $282.45    EPS $0.43 
Volume 54,973